Global Clonorchiasis Market Overview:
Clonorchiasis is a common infection of dogs and other fish-eating carnivores in China, the Democratic People’s Republic of Korea, the Republic of Korea, and Viet Nam. but some patients may have a fever, rash, malaise, and right upper quadrant abdominal discomfort. Chronic infections may be manifested as recurrent pyogenic cholangitis, cholecystitis, obstructive jaundice, hepatomegaly, cholecystitis, multiple hepatic tumors, cholelithiasis, pancreatitis, and cholangiocarcinoma. Clonorchiasis is still highly prevalent among inhabitants in the riverside areas of southern Korea.
- The Increasing Prevalence of Chronic Diseases
- Increasing Expenditure to Boost the Penetration Rate of Treatments of the Clonorchiasis Diseases
- The Growing Acceptance of the Vaccines for the Prevention and Control of Clonorchiasis Diseases
- Increased Drug Resistance
- The Rising Initiatives and Programs to Eliminate Clonorchiasis Diseases
- Increasing Clinical Trial Studies for the Development of New Drugs
- Lack of Effective Therapies
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Pfizer (United States), Bayer AG (Germany), Provet (Switzerland), Virbac (India), Cipla (India), Novartis AG (Switzerland), CIRON Drugs & Pharmaceuticals Pvt. Ltd. (India), Merck & Co., Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland) and Abbott (United States). Additionally, following companies can also be profiled that are part of our coverage like Arsanis, Inc. (Austria), Novabiotics (United Kingdom), GlaxoSmithKline plc. (United Kingdom) and Teva Pharmaceutical Industries Ltd (Taiwan). Analyst at AMA Research see European and United States Players to retain maximum share of Global Clonorchiasis market by 2025. Considering Market by Treatment, the sub-segment i.e. Praziquantel will boost the Clonorchiasis market. Considering Market by Parasites, the sub-segment i.e. Clonorchis Sinensis will boost the Clonorchiasis market. Considering Market by Diagnosis, the sub-segment i.e. Microscopic Examination will boost the Clonorchiasis market. Considering Market by End User, the sub-segment i.e. Hospital will boost the Clonorchiasis market.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Clonorchiasis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Clonorchiasis market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Clonorchiasis Drug Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Other.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.